pharma · Primary Mitochondrial Myopathy · Advanced Solid Tumors, Advanced Breast Cancer · OKUR
OnKure Therapeutics
OnKure Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker OKUR. Primary therapeutic focus areas include Primary Mitochondrial Myopathy, Advanced Solid Tumors, Advanced Bre
Boulder, USA HQ
2011 Founded
42 Employees
Public company Type
OKUR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2011
- Employees
- 42
- Programs
- 8
- Drugs
- 4
- Patents
- 7
REN001
Phase 3 · small molecule · Primary Mitochondrial Myopathy
REN001 for Primary Mitochondrial Myopathy is a Phase 3 program (small_molecule) at OnKure Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code REN001-202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- OnKure Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Primary Mitochondrial Myopathy
- Status
- terminated
- Trials
- 2